Thread: Cord Blood America Inc. - CBAI

done on last tuesday but released for viewing on this past weekend.

--------------------------------------------------------------------------------

MoneyTV With Donald Baillargeon, Week of 6/12
Date : 06/12/2009 @ 5:00AM
Source : MarketWire
Stock : MoneyTV; Cord Blood America, Inc.; Naturally Iowa, Inc.; 1st Glo (CBAI)
Quote : 0.0042 0.0001 (2.44%) @ 7:57AM

MoneyTV With Donald Baillargeon, Week of 6/12





LOS ANGELES, CA -- (Marketwire) -- 06/12/09 -- MoneyTV, hosted by anchor Donald Baillargeon, is the internationally syndicated television program all about money and what makes it happen, (MoneyTV), featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.




Free information packages from the featured companies can be requested by sending an email to info@moneytv.net.





The television program can also be viewed online immediately at MoneyTV.




Featured companies on this week's program include:



Cord Blood America, Inc. (OTCBB: CBAI) CEO Matthew Schissler announced a significant reduction of debt, discussed CBE stem cells and the business of umbilical stem cell storage.

Check out this stem cell related stock. Cord Blood America Inc. Currently under a penny and is an OTC BB stock, fully reporting, and did over $5M in revenue last year. CEO says they are currently #4 in there field and plan to grow thru acqusition. Just watch the CEO on the clip below and you will see how promising this stock is.


This Week on MoneyTV

http://www.cordblood-america.com/

everything from soup to nuts for this company.

mgmt updates almost every pr and viewing possible imho.

their website is awesome imho.

CEO says CBAI is the 4th largest in the USA (at min 6:23) and about the 20th largest of about 150 companies worldwide. Plans on more acquisitions. YouTube - MoneyTV-Stem cell research poised for growth during Obama administration


Websites:
http://www.cordblood-america.com
Umbilical Cord Blood Banking, Storage, Stem Cell Bank Preservation Corcell
Cord Blood Banking Video Center
CURESOURCE HAS JOINED THE CORD BLOOD AMERICA FAMILY OF COMPANIES
Umbilical Cord Blood Banking, Storage, Stem Cell Bank Preservation Corcell

CBAI is one of my best pick for both short and long play

closing not bad today. volume o.k. --- need 100mil share trading days to get back to a penny.

I've been holding CBAI for about 4 months and add to my position while it is down. I think it is going to go up in price soon they have started the process of aquiring or building their own lab. and I think that when more people find this gem it may soar up the charts.

they are 4th in domestic and 20th in worldwide networing ideas.

Last Trade: 0.0036
Change: 0 ("0.00%")
Previous Close: 0.0036
Open: 0.0037
Day's Range: 0.0036-0.0038
52wk Range: 0.09 - 1.10
Volume: 6118361
Market Cap: 5.7M

Keep this stock on your radar. Im my opinion it's a great long-term play. Here is what the CEO recently said regarding Cord Blood's 1Q09 results. The true test of a company is cash flow, and he has also recently stated they expect to soon have a positive cash flow.


"During the first quarter, we took significant initiatives to position the Company for growth,' said Matthew Schissler, Founder and CEO. 'We shifted our business focus to capitalize on the opportunities in the processing of umbilical cord blood, deemphasizing the advertising business, as reflected by our improved gross margin. We believe that the new administration will further support growth in the stem cell industry, and in our business of collecting and storing umbilical cord blood lifting the current ban on Federal funding for research on embryonic stem cell lines. The funding should accelerate the use of stem cells in treating diabetes, heart disease, and other major diseases, driving consumers to make the investments in storage and collection. We also strengthened our balance sheet, reducing indebtedness, extending maturities and regaining compliance with all of our key lenders,' continued Schissler. 'We believe with our improved financial condition that Cord Blood America is now well-positioned to consolidate the industry as well as to acquire or build its own state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells, which should further improve gross margin and profitability. We believe that the Company is well positioned to play a key role as stem cell therapies become a viable treatment modality.'